Unit­edHealth Group will use Pralu­ent, one of two new fed­er­ally ap­proved choles­terol-low­er­ing drugs, in its for­mu­la­ries.

Modern Healthcare - - LATE NEWS -

Sanofi and Re­gen­eron Phar­ma­ceu­ti­cals make the PCSK9 in­hibitor, which treats pa­tients who have high choles­terol lev­els but don’t re­spond to statins. In­sur­ers usu­ally re­ceive dis­counts for plac­ing drugs on the pre­ferred tier, which drives use. The re­tail price for Pralu­ent is $14,600 an­nu­ally, while its com­peti­tor, Repatha, costs $14,100. The In­sti­tute for Clin­i­cal and Eco­nomic Re­view, a not-for-profit re­search group, said the prices for Pralu­ent and Repatha would have to drop by more than 80% to be a good deal for the health­care sys­tem and pa­tients.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.